Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TARACTAN is an injectable small-molecule antipsychotic approved in 1962 by Roche. The drug's specific mechanism of action and therapeutic indications are not detailed in available records, though its injectable formulation suggests use in acute psychiatric settings. As a legacy neuroleptic, it represents an early generation of antipsychotic therapy.
With LOE approaching and minimal current clinical pipeline activity, commercial teams face declining revenue and shrinking headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TARACTAN offers limited career growth opportunities due to LOE status and zero linked job openings. This product is best suited for professionals with expertise in legacy brand management, regulatory compliance, or portfolio optimization in decline phase.
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.